Resources

Cool Veoza tools for your practice

Simplify the VMS conversation with easy-to-use VEOZA resources

Download or share resources below
Provider

Mechanism of action (MOA) flashcard

Quickly reference VEOZA in your practice.

Download

MOA video

Watch the mechanism of action of VEOZA.

See the video

Frequently asked questions

VEOZA is a neurokinin 3 (NK3) receptor antagonist for the treatment of moderate to severe Vasomotor Symptoms (VMS) associated with menopause, also known as hot flushes and night sweats.1,2

 
VEOZA is not a hormone. It is a VMS treatment that directly blocks NKB binding, a known trigger of VMS associated with menopause.1,3,4 It is a selective NK3 receptor antagonist that blocks NKB binding on the KNDy neuron to modulate neuronal activity in the temperature control centre. This action helps to reduce the number and intensity of hot flushes and night sweats.1

KNDy: kisspeptin/neurokinin B/dynorphin, NK3: neurokinin 3, NKB: neurokinin B.

WATCH THE MOA VIDEO

VEOZA demonstrated statistically significant reductions from baseline in the frequency and severity of moderate to severe VMS over 24 hours compared to placebo, at weeks 4 and 12.1* The efficacy of VEOZA was evaluated in two 12-week, randomised, placebo-controlled, double-blind Phase 3 studies, followed by a 40-week extension treatment period.1

*Statistically significantly superior compared to placebo at the 0.05 level with multiplicity adjustment.1

SEE THE FULL STUDY RESULTS

VEOZA 45 mg should be taken orally once daily with liquids, with or without food. VEOZA should be swallowed whole. Do not cut, crush, or chew tablets. Patients can choose what time to take it, but should adhere to the same time each day.1

 

SEE DOSING

Across the Phase 3 studies, the most common adverse reactions (≥3%) with VEOZA 45 mg were diarrhoea (3.2%) and insomnia (3.0%). The most frequent adverse reactions leading to dose discontinuation with VEOZA were alanine aminotransferase (ALT) increased (0.3%) and insomnia (0.2%).

EXPLORE THE SAFETY OF VEOZA

Practice resources are available to help you quickly reference VEOZA.

REFERENCES: 1. VEOZA [Veoza Israeli SmPC] 2. Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et al., eds. Menopause Practice: A Clinician’s Guide. 6th ed. Pepper Pike, OH: The North American Menopause Society, 2019:43-55. 3. Depypere H, Lademacher C, Siddiqui E, Fraser GL. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs 2021;30(7):681-94. 4. Jayasena CN, Comninos AN, Stefanopoulou E, et al. Neurokinin B administration induces hot flushes in women. Sci Rep (Epub) 02-16-2015.